uniQure (NASDAQ:QURE) Posts Earnings Results, Misses Expectations By $0.90 EPS

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.90), Zacks reports. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

uniQure Price Performance

NASDAQ QURE traded up $0.40 during mid-day trading on Thursday, hitting $12.07. The stock had a trading volume of 1,203,214 shares, compared to its average volume of 1,018,131. The firm’s 50 day moving average is $15.19 and its 200 day moving average is $9.73. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $588.33 million, a price-to-earnings ratio of -2.43 and a beta of 0.39.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on QURE. Stifel Nicolaus increased their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $40.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.